Advances in tumor immune microenvironment of head and neck squamous cell carcinoma: A review of literature

Qichao Hong,Shun Ding,Chengliang Xing,Zhonglin Mu
DOI: https://doi.org/10.1097/md.0000000000037387
IF: 1.6
2024-03-13
Medicine
Abstract:Head and neck cancer is regarded as the seventh most common cancer in the world in the light of the Global Cancer Report 2020. With annual new incidence and death rates increasingly growing year by year, head and neck squamous cell cancer carcinoma (HNSCC) is viewed as the most common type yet of cancer. [ 1 , 2 ] The current treatment plan for HNSCC is mainly the comprehensive treatment combined with surgery, radiotherapy and chemotherapy. In recent years, there exist many different ways including traditional Chinese medicine therapy, molecular targeted therapy, immunotherapy and other treatment methods which have gradually been paid tremendous attention by people. [ 3 ] In advanced tumors, however, these treatments are often less effective. And the main causes of death in patients suffering from advanced HNSCS are concerned with local recurrence, lymphatic metastases in the neck and standard chemotherapy as well as drug resistance, which all will result in treatment failure. [ 4 ] Although patients with the later-stage HNSCC have been treated, the 5-year survival rate for them still remains quite low, at about 40% to 50%. [ 5 ] Therefore, it is a key clue to seek an effective therapeutic target or prognostic biomarker.
medicine, general & internal
What problem does this paper attempt to address?